Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

[Chemotherapy and MSI status].

des Guetz G, Schischmanoff PO.

Gastroenterol Clin Biol. 2005 Oct;29(10):1040. French. No abstract available.

PMID:
16435513
2.

Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a prognostic marker?

Watanabe T, Kanazawa T, Tada T, Kazama Y, Hata K, Nagawa H.

Gastroenterology. 2004 Aug;127(2):688-9; author reply 689-90. No abstract available.

PMID:
15300610
3.

Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.

Johnson L, Chu E.

Clin Colorectal Cancer. 2002 Nov;2(3):146-8. Review. No abstract available.

PMID:
12482330
4.
5.
6.

Can we predict response to 5-FU?

McCann J.

J Natl Cancer Inst. 2000 Dec 20;92(24):1976-7. No abstract available.

PMID:
11121459
7.

Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.

Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E.

Eur J Cancer. 2010 Oct;46(15):2788-98. doi: 10.1016/j.ejca.2010.05.009. Epub 2010 Jun 4. Review.

PMID:
20627535
8.

Microsatellite instability in colon cancer.

Allegra CJ, Kim G, Kirsch IR.

N Engl J Med. 2003 Oct 30;349(18):1774-6; author reply 1774-6. No abstract available.

9.

Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Jover R, Castells A, Llor X, Andreu M.

Gut. 2006 Dec;55(12):1819-20. No abstract available.

10.

Tumour site, sex, and survival in colorectal cancer.

Rosell R, Abad A.

Lancet. 2000 Sep 2;356(9232):857; author reply 858. No abstract available.

PMID:
11022957
11.

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.

PMID:
18722765
12.

Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis.

Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF.

Anticancer Res. 2009 May;29(5):1615-20. Review.

13.

Tumour site, sex, and survival in colorectal cancer.

Scott RJ, Spigelman AD.

Lancet. 2000 Sep 2;356(9232):857; author reply 858. No abstract available.

PMID:
11022958
14.

Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR.

Gastroenterology. 2004 Feb;126(2):394-401.

PMID:
14762775
15.

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

Gamelin E, Boisdron-Celle M.

Crit Rev Oncol Hematol. 1999 Mar;30(1):71-9. Review. No abstract available.

PMID:
10439055
16.

Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.

Webber EM, Kauffman TL, O'Connor E, Goddard KA.

BMC Cancer. 2015 Mar 21;15:156. doi: 10.1186/s12885-015-1093-4. Review.

17.

Therapy for colorectal cancer.

Jankilevich G.

N Engl J Med. 2005 Apr 28;352(17):1820-2; author reply 1820-2. No abstract available.

PMID:
15864822
18.

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B.

Eur J Cancer. 2009 Jul;45(10):1890-6. doi: 10.1016/j.ejca.2009.04.018. Epub 2009 May 6. Review.

PMID:
19427194
19.

The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site.

Elsaleh H.

Gastroenterology. 2001 Jul;121(1):230-1. No abstract available.

PMID:
11441888
20.

High thymidylate synthase expression is typical for sporadic MSI-H colorectal carcinoma.

Okoń K, Klimkowska A, Wójcik P, Osuch C, Papla B, Stachura J.

Pol J Pathol. 2006;57(1):29-33.

PMID:
16739880

Supplemental Content

Support Center